Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

(2010) S-J Dawson et al.   BRITISH JOURNAL OF CANCER

Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect

(2010) M. Li et al.   MOLECULAR CANCER THERAPEUTICS

Low Dose Estrogen Supplementation Reduces Mortality of Mice in Estrogen-Dependent Human Tumor Xenograft Model

(2009) Jong Soon Kang et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

(2009) Grace M Callagy et al.   BMC CANCER

Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non-Small Cell Lung Tumor Xenograft Model

(2009) K. W. Kim et al.   CLINICAL CANCER RESEARCH

A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer

(2009) Ikuo Sekine et al.   International Journal of Clinical Oncology

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia

(2009) K D Mason et al.   LEUKEMIA

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

(2009) Elgene Lim et al.   NATURE MEDICINE

Differences and Molecular Immunohistochemical Parameters in the Subtypes of Infiltrating Ductal Breast Cancer

(2008) Cristina Bertolo et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

(2008) L. Paoluzzi et al.   BLOOD

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Alteration of the Mitochondrial Apoptotic Pathway Is Key to Acquired Paclitaxel Resistance and Can Be Reversed by ABT-737

(2008) O. Kutuk et al.   CANCER RESEARCH

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer

(2008) C. L. Hann et al.   CANCER RESEARCH

Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737

(2008) K. Okumura et al.   CLINICAL CANCER RESEARCH

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION

Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins

(2008) J. E. Chipuk et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA